textabstractBACKGROUND: We compared two recently developed research assays for the measurement of human kallikrein 2 (hK2) in serum: one fully automated assay (Beckman Coulter Access immunoanalyzer) and one manual assay based on the DELFIA technology. METHODS: We used two subsets of clinical specimens consisting of 48 samples from prostate cancer patients and 210 samples from participants in an ongoing screening study (ERSPC). Both subsets were measured in the Rotterdam laboratory, and the prostate cancer samples were used for analytical comparison with the originating sites for the assays: Beckman Coulter Research Department (San Diego, CA) and Turku University (Turku, Finland). RESULTS...
BACKGROUND: We evaluated the association of total and free forms of serum human kallikrein 2 (hK2) a...
Background: Human glandular kallikrein (hK2) is a serine protease that has 79 % amino acid identity ...
PURPOSE: We measured serum levels of human glandular kallikrein 2 (hK2) in patients with prostate ca...
Background: We compared two recently developed re-search assays for the measurement of human kallikr...
BACKGROUND: Measurement of human kallikrein 2 (hK2) has improved early detection and staging of pros...
has improved early detection and staging of prostate cancer. However, reported concentrations of hK2...
Background: Free and total human kallikrein 2 (hK2) might improve the discrimination between prostat...
PURPOSE: Previously human glandular kallikrein 2 (hK2) has been implicated to predict pathologically...
BACKGROUND: Free and total human kallikrein 2 (hK2) might improve the discrimination between prostat...
Purpose: Previously human glandular kallikrein 2 (hK2) has been implicated to predict pathologically...
Purpose: We investigated the value of serum measurements for glandular kallikrein 2 (hK2), and free ...
OBJECTIVES: To investigate the clinical value of human glandular kallikrein 2 (hK2) compared with fr...
Purpose: We investigated the value of serum measurements for glandular kallikrein 2 (hK2), and free ...
Background: Free and total human kallikrein 2 (hK2) might improve the discrimination between prostat...
Background: We evaluated the association of total and free forms of serum human kallikrein 2 (hK2) a...
BACKGROUND: We evaluated the association of total and free forms of serum human kallikrein 2 (hK2) a...
Background: Human glandular kallikrein (hK2) is a serine protease that has 79 % amino acid identity ...
PURPOSE: We measured serum levels of human glandular kallikrein 2 (hK2) in patients with prostate ca...
Background: We compared two recently developed re-search assays for the measurement of human kallikr...
BACKGROUND: Measurement of human kallikrein 2 (hK2) has improved early detection and staging of pros...
has improved early detection and staging of prostate cancer. However, reported concentrations of hK2...
Background: Free and total human kallikrein 2 (hK2) might improve the discrimination between prostat...
PURPOSE: Previously human glandular kallikrein 2 (hK2) has been implicated to predict pathologically...
BACKGROUND: Free and total human kallikrein 2 (hK2) might improve the discrimination between prostat...
Purpose: Previously human glandular kallikrein 2 (hK2) has been implicated to predict pathologically...
Purpose: We investigated the value of serum measurements for glandular kallikrein 2 (hK2), and free ...
OBJECTIVES: To investigate the clinical value of human glandular kallikrein 2 (hK2) compared with fr...
Purpose: We investigated the value of serum measurements for glandular kallikrein 2 (hK2), and free ...
Background: Free and total human kallikrein 2 (hK2) might improve the discrimination between prostat...
Background: We evaluated the association of total and free forms of serum human kallikrein 2 (hK2) a...
BACKGROUND: We evaluated the association of total and free forms of serum human kallikrein 2 (hK2) a...
Background: Human glandular kallikrein (hK2) is a serine protease that has 79 % amino acid identity ...
PURPOSE: We measured serum levels of human glandular kallikrein 2 (hK2) in patients with prostate ca...